G. Walmsley Graham - 30 Nov 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
30 Nov 2023
Net transactions value
+$1,694,565
Form type
4
Filing time
05 Dec 2023, 08:37:03 UTC
Previous filing
18 Dec 2023
Next filing
11 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Purchase $844,835 +50,000 +8.3% $16.90 650,000 30 Nov 2023 See Footnote F1
transaction AKRO Common Stock Purchase $849,730 +50,000 +7.7% $16.99 700,000 01 Dec 2023 See Footnote F1
holding AKRO Common Stock 2,168 30 Nov 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.